Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 8

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 8
---
 Placement included the
issuance of Common Shares, 2023 Pre-Funded Warrants, and 2023 Common Warrants
to related parties namely (i) Shore Pharma LLC, an entity that was controlled
by Vimal Kavuru, , the Chair of the Company’s Board of Directors, at the time
of the 2023 Private Placement and (ii) SS Pharma LLC, the beneficial owner of
5.5% of Common Shares outstanding prior to the 2023 Private Placement,
resulting in proceeds of $2,500. 
  In October 2025, the Company
received $4,000 in gross proceeds from exercises of 1,345,464 common warrants that
were previously issued in a private placement in September 2023 for 1,345,464
shares of Common Stock. The remaining 1,190,927 common warrants issued in the
2023 private placement have expired in accordance with the terms of the common
warrant as the 60th day after the FDA’s acceptance for review of the Company’s
NDA for GTx-104 has passed.   The following table summarizes the Company’s outstanding warrants as of September 30, 2025, all of which are exercisable for shares of Common Stock:  

      September 30, 2025

      No. of warrants 
      ExercisePrice ($) 
     ExpirationDate

      Liability classified warrants (Derivative Warrant Liabilities)

      Common warrants issued in connection with 2023 Private Placement (2023 Common Warrants)

      2,536,391 
      3.003 
      (1) 

      Equity classified warrants

      Pre-funded warrants issued in connection with 2023 Private Placement (2023 Pre-Funded Warrants)

      808,502 
      0.0001 

      No expiration

      Common warrants issued in connection with 2025 Private Placement (2025 Common Warrants)

      4,418,291 
      3.395 
     (2) 

      Pre-funded warrants issued in connection with 2025 Private Placement (2025 Pre-Funded Warrants)

      987,458 
      0.0001 

      No expiration

    (1) Following the
exercise of 1,345,464 2023 Common Warrants in October 2025, the remaining 1